Jonathan Rosenberg
MD
Chief, Genitourinary Oncology
👥Biography 个人简介
Jonathan Rosenberg at MSK has been a leading researcher in urothelial cancer, including contributions to landmark trials establishing enfortumab vedotin (nectin-4 ADC) plus pembrolizumab as first-line standard of care for advanced urothelial cancer (EV-302 trial) — showing dramatic improvement in survival versus platinum-based chemotherapy. His work on ADC development in urothelial cancer and immunotherapy combinations has transformed the treatment of this disease.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Jonathan Rosenberg 的研究动态
Follow Jonathan Rosenberg's research updates
留下邮箱，当我们发布与 Jonathan Rosenberg（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment